Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.
Saved in:
| Title: | Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study. |
|---|---|
| Authors: | Kiladjian JJ; Saint-Louis Hospital, Paris Cité University, INSERM, Paris 75010, France., Borate U; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The James Outpatient Care, Columbus, OH 43210, United States., Abruzzese E; S. Eugenio Hospital, Tor Vergata University, Rome 00144, Italy., De Stefano V; Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome 00168, Italy., Gong T; Harbin Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, Heilongjiang 150010, China., Breccia M; Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome 00161, Italy., Palandri F; Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 40138, Italy., Pane F; Department of Clinical Medicine and Surgery, University Federico II, Naples 80131, Italy., Patriarca A; Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara 28100, Italy., Reikvam H; Department of Clinical Science, K.G. Jebsen Center for Myeloid Blood Cancer, University of Bergen, Bergen 5009, Norway.; Department of Medicine, Haukeland University Hospital, Bergen, 5009, Norway., Rein L; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States., Yacoub A; Department of Internal Medicine, University of Kansas Medical Center, Westwood Campus, Westwood, KS 66205, United States., Zhou F; Incyte Corporation, Wilmington, DE 19803, United States., Stouffs M; Incyte Corporation, Wilmington, DE 19803, United States., Assad A; Incyte Corporation, Wilmington, DE 19803, United States., Vannucchi AM; Department of Experimental and Clinical Medicine, University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence 50134, Italy. |
| Source: | The oncologist [Oncologist] 2026 Jun 06; Vol. 31 (7). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1093/oncolo/oyag201 |
